CoChat
Cited by 215

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Neural stem cell delivery of an oncolytic adenovirus in newly diagnosed malignant glioma: a first-in-human, phase 1, dose-escalation trial

Open access
Fares, Jawad, Ahmed, Atique U, Ulasov, Ilya V, Sonabend, Adam M, Miska, Jason, Lee-Chang, Catalina, Balyasnikova, Irina V, Chandler, James P, Portnow, Jana, Tate, Matthew C, Kumthekar, Priya, Lukas, Rimas V, Grimm, Sean A, Adams, Ann K, Hébert, Charles D, Strong, Theresa V, Amidei, Christina, Arrieta, Victor A, Zannikou, Markella, Horbinski, Craig, Zhang, Hui, Burdett, Kirsten Bell, Curiel, David T, Sachdev, Sean, Aboody, Karen S, Stupp, Roger, Lesniak, Maciej S · 2021 · The Lancet Oncology

Abstract

SUMMARY Background: Malignant glioma is the most common and lethal primary brain tumor, with dismal survival rates and no effective treatment. We examined the safety and therapeutic potential of NSC-CRAd-S-pk7, an engineered oncolytic adenovirus delivered by neural stem cells (NSCs), in patients with newly diagnosed high-grade glioma. Methods: A first-in-human, open-label, phase 1, dose-escalation clinical trial was conducted to determine the maximal tolerated dose of NSC-CRAd-S-pk7, following a 3+3 design. Patients with newly diagnosed high-grade gliomas (WHO Grade III or IV), confirmed by histological testing, were recruited. After neurosurgical resection, NSC-CRAd-S-pk7 was injected into the walls of the resection cavity. The first patient cohort received the first dose level starting at 6.25×1010 viral particles (vp) administered via 50 million NSCs, followed by the second patient cohort with the second dose level of 1.25×1011 vp administered via 100 million NSCs, and the third cohort received 1.875×1011 vp administered via 150 million NSCs. No further dose escalation was planned. Within 10–14 days, treatment with temozolomide and radiotherapy was initiated. Assessment was done through medical history, imaging, blood samples, and chemistry values that were collected at screening and follow-up. Tissue analysis for cytokines and immune infiltrates was also performed. Primary endpoints were safety and tolerability. Secondary endpoints included the estimation of survival outcomes in patients, and the evaluation of whether clinical outcomes correlated with the extent of the immune response. All analyses were done in all patients who were included in the trial and received the study treatment and were not excluded from the study. Recruitment is complete and the trial is finished. The trial is registered with ClinicalTrials.gov, NCT03072134. Findings: Between April 24, 2017 and November 13, 2019, 12 patients with newly diagnosed, malignant gliomas were recruited and included in the safety analysis. The median follow-up was 18 months (IQR 14–22). Histopathological evaluation identified 11 (92%) of 12 patients with glioblastoma and one (8%) of 12 patients with anaplastic astrocytoma. Treatment was safe as no formal dose-limiting toxicity was reached. One patient developed viral meningitis (grade 3) due to the inadvertent injection of NSC-CRAd-S-pk7 into the lateral ventricle. Post-mortem tissue exploration showed that NSC-CRAd-S-pk7 was effectively cleared from the brain. There were no treatment related deaths. The median progression-free survival and overall survival were 9.05 months (95% CI 8.54, NA) and 18.4 months (95% CI 15.7, NA), respectively. Interpretation: NSC-CRAd-S-pk7 elicited an immune-mediated anti-glioma response and showed promising survival outcomes, especially in patients with MGMT unmethylated tumors. Exploratory immunological results support continued investigation of NSC-CRAd-S-pk7 with multiple injections through an intracranial catheter and/or its combination with anti-PD-1 immunotherapy in a higher phase trial with a larger cohort of patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s1470-2045(21)00245-x

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 215

Metadata

Authors
Fares, J., Ahmed, A. U., Ulasov, I. V., Sonabend, A. M., Miska, J., Lee-Chang, C., Balyasnikova, I. V., Chandler, J. P., Portnow, J., Tate, M. C., Kumthekar, P., Lukas, R. V., Grimm, S. A., Adams, A. K., Hébert, C. D., Strong, T. V., Amidei, C., Arrieta, V. A., Zannikou, M., Horbinski, C., Zhang, H., Burdett, K. B., Curiel, D. T., Sachdev, S., Aboody, K. S., Stupp, R., & Lesniak, M. S.
Venue
The Lancet Oncology
Publisher
Elsevier BV
Published
2021-08
Volume
22
Issue
8
Pages
1103-1114
ISSN
1470-2045 (ISSN-L)
OpenAlex
W3174421288
Cited by
215
References
4
FWCI
16.24
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Neural stem cell delivery of an oncolytic adenovirus in newly diagnosed malignant glioma: a first-in-human, phase 1, dose-escalation trial. https://app.cochat.ai/papers/10.1016/s1470-2045(21)00245-x
The paper
Fares, J., Ahmed, A. U., Ulasov, I. V., Sonabend, A. M., Miska, J., Lee-Chang, C., Balyasnikova, I. V., Chandler, J. P., Portnow, J., Tate, M. C., Kumthekar, P., Lukas, R. V., Grimm, S. A., Adams, A. K., Hébert, C. D., Strong, T. V., Amidei, C., Arrieta, V. A., Zannikou, M., . . . Lesniak, M. S. (2021). Neural stem cell delivery of an oncolytic adenovirus in newly diagnosed malignant glioma: a first-in-human, phase 1, dose-escalation trial. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(21)00245-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.